Dr. Seth Y. Ablordeppey Awarded NIH R16 Grant

Dr. Seth Y Ablordeppey, Professor and Eminent Scholar Chair in Biomedical Sciences, has been awarded a National Institutes of Health, National Institute of General Medical Sciences R16 grant. His project, "Discovery of a High Affinity, Selective and b-arrestin Biased 5-HT7R Agonist,” is funded at $148,000 per year over four years for $592,000. Please join us in congratulating Dr. Ablordeppey on this phenomenal achievement.

Dr. Ablordeppey is the first at FAMU to be awarded a grant under this new National Institutes of Health, National Institute of General Medical Sciences R16 funding mechanism and, indeed, among the first cohort of recipients in the Nation.

The three goals of the grant are to evaluate and optimize newly discovered agents under development for multiple health conditions. This includes:

1. Obtaining new medications that treat sleep disorders that affect between 50 -70 million adults in this country.
2. Producing new pain medications without the addiction associated with current opioid medications.
3. Obtaining new drugs with the potential to treat drug addiction.

The award start date is 4/15/2022, and the end date of 3/31/2026. Please join us in congratulating Dr. Ablordeppey on this phenomenal achievement.